Izotropic Corporation (IZOZF)
| Market Cap | 12.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.44M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,389 |
| Average Volume | 27,919 |
| Open | 0.1925 |
| Previous Close | 0.2100 |
| Day's Range | 0.1900 - 0.2025 |
| 52-Week Range | 0.0186 - 0.3300 |
| Beta | 2.18 |
| RSI | 48.88 |
| Earnings Date | Aug 26, 2025 |
About Izotropic
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses. Izotropic Corporation was incorporated in 2016 and is headquartered in Surrey, Canada. [Read more]
News
Izotropic Prepares New Platforms to Educate and Engage
- Strategic awareness initiatives underway ahead of IzoView commercialization - - Company podcast and breasct.com website in development to expand engagement - - Market-facing activities aligned with ...
Izotropic Provides Marketing Update
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device c...
Izotropic Revises License Agreement with The Regents of the University of California
- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) - - Amendment aligns with Company's timelines for IzoView product launch - - Agreement amendment fees of USD $85K payable ...
Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
- Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial - - 150-page strategic business plan and advanced financial models completed - - Investor outreach launched to f...
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device c...
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
- FDA meeting facilitated positive collaborative exchange - - Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast ...
Izotropic to Present at Investor Conference March 13th
- CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models - - Event includes live Q and A, attendance is complimentary - - Individual and institutional investo...
FDA Sets Meeting Date with Izotropic
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical devi...
Izotropic Closes Non-Brokered Private Placement
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 14, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical devi...
Izotropic Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 7, 2025) -...
Izotropic Reschedules Investor Conference Presentation to March 13th
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 5, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical devic...
Izotropic to Present at Investor Conference February 6th
- CEO to present overview of Company value proposition, unique catalysts, and near-term objectives - - Event includes live Q and A, attendance is complimentary - - Individual and institutional investo...
Izotropic Announces Timelines and Milestones to IzoView Product Launch
- Unique dense breast tissue focus to drive expedited recruitment rates; modular clinical study design reduces time to PMA submission by ~6 months - - 3 Site U.S.-based clinical study enables early da...
Izotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and Forecast
- Company listed in Research and Markets' announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - "U.S. breast cancer screening and diagnostic ...
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
-New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration- -New Biostatistical Consultant is the former Deput...
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
-A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800% 1 for initial approval and product launch- -Reg...
Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing I...
Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU
Vancouver, British Columbia--(Newsfile Corp. - August 23, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing Iz...
Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's news release of Jun...
Izotropic Corporation Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoVi...
Izotropic Receives Response From U.S. FDA
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing I...
Izotropic Provides Regulatory and Operational Updates
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing Iz...
Izotropic Completes Pre-Submission Meeting with U.S. FDA
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing I...
Izotropic Confirms FDA Pre-Submission Meeting Date
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing...
Izotropic Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializin...